Article
The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.
All News
Article
Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.com
“Climate is what we expect, weather is what we get.” – Mark Twain
Article
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.
This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.
Article
In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.
Dr. John Cush
Tweet
Review of VTE risk with JAK inhibitors
- Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY
- Baricitinib: IR of DVT/PE was 0.5/100PY
- Filgotinib: 200mg VTEs 0.2/100PY
Most VTE occured in LT extension of RCT https://t.co/xvf0kQUMel https://t.co/Bj6fmkktP7
Dr. John Cush
Tweet
Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.
Are you a fan of our podcast? Please rate, like and review us wherever you get your podcast.
https://t.co/uj6QF3EqlU https://t.co/lFpoRfkEqU
Dr. John Cush
Tweet
Melatonin Use Growing, Inappropriate & Potentially Unsafe
With nearly 1/3 of adults, adolescents and children having sleep difficulties, many resort to using melatonin. But is it effective, safe and warranted?
https://t.co/8TA76yAbwr https://t.co/ADYklo0yMz
Dr. John Cush
Tweet
Olokizumab, another IL-6 Inhibitor for RA
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA).
https://t.co/VMz8xzffiZ https://t.co/eaA4CUWvrv
Dr. John Cush
Tweet
Hyaluronic Acid Knee Injections Equivalent to Placebo
In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.
https://t.co/1pSVr3VI4t https://t.co/DvFN7WQdTp
Dr. John Cush
Tweet
Bullous Systemic Lupus Erythematosus (BSLE)
BSLE is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
https://t.co/TBr7pGXjZ5 https://t.co/aq5dX3wQPX
Dr. John Cush
Tweet
Record Use of Marijuana and Hallucinogens in Young Adults
The NY Times reports that a recent survey of drug use indicates that daily consumption of marijuana among young adults nearly doubled in the last decade.
https://t.co/Dvj4nUNdtg https://t.co/BRkq8nb5sz
Dr. John Cush
Tweet
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/3TavS7NE99 https://t.co/lZyp1QLNqP
Dr. John Cush
Tweet
Myths & Misconceptions with Febrile Disorders
Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs.
https://t.co/vdZWR1cwDx https://t.co/OoGIBjpZGn
Dr. John Cush
Tweet
Top 60 brand-name drugs in US cost ~395%higher than other high-income countries. New legislation by Congress lets Medicare negotiate drug prices & cap out-of-pocket costs @$2,000/yr. Read more on proposed restrictions importing drugs from Canada https://t.co/z507qRNj4E https://t.co/kXnqIQkIp7
Dr. John Cush
Tweet
Study of 9611 pts w/ hip or knee arthroplasty for #OA tested aspirin (100 mg/d) vs enoxaparin (40 mg/d) (x35d w/THA; 14d after TKA). Enrollment prematurely halted as VTE rate was 3.45% w/ ASA and 1.8% w/ enoxaparin (superior to ASA: P= .007) https://t.co/jvuely8L56 https://t.co/O1TxCjaSPU
Dr. John Cush
Tweet
VTE (clots) w/ JAK inhibitors? Metanalysis of JAKi in 9711 Atopic dermatitits pts shows no significant assoc between JAK and incident VTE (HR 0.95; CI 0.62-1.45; or 0.23 VTE/100PYs). Actual #s: 3 VTE per 5722 pts (0.05%) https://t.co/VesXp5WSpY https://t.co/JsFSKzmbjN
Dr. John Cush
Tweet
Eval of 161 acute mono/oligoarthritis pts (gout, CPPD, controls) shows US of 2 joints (target jt, knee, MTP1, wrist) showed Dx accuracy (>90%), high specificity for gout (0.92-0.96) & CPPD (0.90-0.97); w/ sensitivity ranged from 0.73 to 0.85 for gout https://t.co/hW3pmz86kH https://t.co/IFVpINgybY
Dr. John Cush
Tweet
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI
Dr. John Cush
Tweet
JAMA Patient Handout on common causes of patient hair loss
1. Patterned: androgenetic alopecia
2. Diffuse: telogen effluvium
3. Focal: alopecia areata
https://t.co/caL41RdxaV https://t.co/WsStH3drMk
Dr. John Cush
Tweet
Bidirectional Association Between Depression and Rheumatoid Arthritis
A recent meta-analysis suggests a bidirectional association between RA and depression. Finding RA patients with depression yields an 80% increased mortality risk.
https://t.co/1o2ObHd76V
